Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Peptic Ulcer

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    November 2021
  1. SUGANO K, Howden CW
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.
    Aliment Pharmacol Ther. 2021;54:1350-1351.
    PubMed    


  2. JIANG F, Guo CG, Leung WK
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:1352-1353.
    PubMed    


    October 2021
  3. SCHUITENMAKER JM, Oude Nijhuis RAB, Bredenoord AJ
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:976.
    PubMed    


  4. RIBOLSI M, Savarino E
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?
    Aliment Pharmacol Ther. 2021;54:974-975.
    PubMed    


    September 2021
  5. JIANG F, Guo CG, Cheung KS, Leung WK, et al
    Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study.
    Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16604.
    PubMed     Abstract available


  6. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    PubMed     Abstract available


  7. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    PubMed     Abstract available


    August 2021
  8. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    PubMed     Abstract available


  9. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    PubMed    


  10. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    PubMed    


  11. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    PubMed    


  12. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    PubMed    


  13. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    PubMed    


    July 2021
  14. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    PubMed     Abstract available


  15. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    PubMed    


  16. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    PubMed    


  17. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    PubMed     Abstract available


    June 2021
  18. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    PubMed     Abstract available


  19. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    PubMed     Abstract available


  20. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    PubMed    


    April 2021
  21. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    PubMed     Abstract available


    March 2021
  22. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    PubMed     Abstract available


  23. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    PubMed    


  24. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    PubMed    


  25. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    PubMed    


  26. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    PubMed    


  27. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    PubMed    


    February 2021
  28. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    PubMed     Abstract available


    January 2021
  29. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    PubMed     Abstract available


  30. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    PubMed     Abstract available


    December 2020
  31. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    PubMed     Abstract available


    November 2020
  32. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    PubMed     Abstract available


    September 2020
  33. VERMORKEN AJM, Zhu J, Cui Y
    Letter: does Helicobacter pylori infection limit the health effects of the Mediterranean diet?
    Aliment Pharmacol Ther. 2020;52:935-936.
    PubMed    


  34. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    PubMed    


  35. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    PubMed    


    August 2020
  36. MEI LI C, Brusselaers N
    Letter: safety of proton pump inhibitors during pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:740-741.
    PubMed    


  37. ACAR S, Keskin-Arslan E, Uysal N, Karadas B, et al
    Letter: safety of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020;52:739.
    PubMed    


    July 2020
  38. LABENZ C, Worns MA, Adarkwah CC, Galle PR, et al
    Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
    Aliment Pharmacol Ther. 2020 Jul 30. doi: 10.1111/apt.16008.
    PubMed     Abstract available


  39. CHO YK, Choi MG, Choi SC, Lee KM, et al
    Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
    Aliment Pharmacol Ther. 2020 Jul 23. doi: 10.1111/apt.15865.
    PubMed     Abstract available


  40. LASERNA-MENDIETA EJ, Casabona S, Guagnozzi D, Savarino E, et al
    Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
    Aliment Pharmacol Ther. 2020 Jul 17. doi: 10.1111/apt.15957.
    PubMed     Abstract available


  41. SCHNOLL-SUSSMAN F, Katz PO
    Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:408.
    PubMed    


  42. SUGIYAMA T
    Letter: bone fracture risk among older long-term users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;52:407-408.
    PubMed    


  43. MA ZF, Deraman MA, Coyle C, Lee YY, et al
    Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:398-399.
    PubMed    


  44. KATZ PO, Castell DO
    Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.
    Aliment Pharmacol Ther. 2020;52:397-398.
    PubMed    


    June 2020
  45. YUAN J, Zhang C, Sparks JA, Malspeis S, et al
    Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Jun 29. doi: 10.1111/apt.15834.
    PubMed     Abstract available


  46. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1215-1216.
    PubMed    


  47. GANTUYA B, El-Serag HB, Yamaoka Y
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1447-1449.
    PubMed    


  48. HE C, Peng C, Xia Z, Lu N, et al
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer?
    Aliment Pharmacol Ther. 2020;51:1446-1447.
    PubMed    


  49. SUN Y
    Letter: Helicobacter pylori eradication treatment and the risk of oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1452-1453.
    PubMed    


    May 2020
  50. TWUM-BARIMAH E, Abdelgadir I, Gordon M, Akobeng AK, et al
    Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15761.
    PubMed     Abstract available


  51. ZHANG C, Li N, An Y
    Letter: the relationship between Helicobacter pylori and coronary heart disease.
    Aliment Pharmacol Ther. 2020;51:999.
    PubMed    


    March 2020
  52. KUMAR S, Metz DC, Ginsberg GG, Kaplan DE, et al
    Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15677.
    PubMed     Abstract available


    January 2020
  53. MACKE L, Schulz C, Koletzko L, Malfertheiner P, et al
    Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15604.
    PubMed     Abstract available


  54. LI CM, Zhernakova A, Engstrand L, Wijmenga C, et al
    Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15610.
    PubMed     Abstract available


  55. MCPHERSON SJ, Hammond CJ
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020;51:311-312.
    PubMed    


  56. BARDOU M, Barkun AN
    Editorial: how can we best promote the routine use of scores that are accurate at predicting outcomes in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;51:305-306.
    PubMed    


  57. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.
    Aliment Pharmacol Ther. 2020;51:313-314.
    PubMed    


  58. STANLEY A
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Author's reply.
    Aliment Pharmacol Ther. 2020;51:312-313.
    PubMed    


  59. KURLANDER JE, Rubenstein JH
    Editorial: moving towards the appropriate use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;51:175-176.
    PubMed    


  60. SCHNOLL-SUSSMAN F, Katz PO
    Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:177.
    PubMed    


  61. SCHEIMAN JM
    Commentary: cardioprotective aspirin and gastroduodenal ulcers.
    Aliment Pharmacol Ther. 2020;51:203.
    PubMed    


    October 2019
  62. GHOSH G, Schnoll-Sussman F, Mathews S, Katz PO, et al
    Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?
    Aliment Pharmacol Ther. 2019 Oct 30. doi: 10.1111/apt.15522.
    PubMed     Abstract available


  63. SAFFOURI E, Blackwell C, Laursen SB, Laine L, et al
    The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2019 Oct 23. doi: 10.1111/apt.15541.
    PubMed     Abstract available


  64. GUO CG, Cheung KS, Zhang F, Chan EW, et al
    Risks of hospitalization for upper gastrointestinal bleeding in selective serotonin reuptake inhibitors users after Helicobacter pylori eradication therapy: a propensity score matching analysis.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15507.
    PubMed     Abstract available


    April 2019
  65. WONG GL, Ma AJ, Deng H, Ching JY, et al
    Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding.
    Aliment Pharmacol Ther. 2019;49:912-918.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: